These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27069936)

  • 1. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients.
    Qian L; Wang N; Tian H; Jin H; Zhao H; Niu C; He H; Ge T; Han W; Hu J; Li D; Han F; Xu J; Ding X; Chen J; Li W; Cui J
    J Immunol Res; 2016; 2016():6837241. PubMed ID: 27069936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.
    Cui J; Wang N; Zhao H; Jin H; Wang G; Niu C; Terunuma H; He H; Li W
    Int J Cancer; 2014 Jan; 134(2):342-51. PubMed ID: 23825037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
    Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
    Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
    Marotta F; Vangieri B; Cecere A; Gattoni A
    Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma.
    Cui J; Li L; Wang C; Jin H; Yao C; Wang Y; Li D; Tian H; Niu C; Wang G; Han W; Xu J; Chen J; Li W
    Cytotherapy; 2015 Jul; 17(7):979-88. PubMed ID: 25890480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
    Kalathil SG; Thanavala Y
    Cells; 2021 May; 10(6):. PubMed ID: 34071188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Th1 and Th2 cytokine profiles induced by hepatitis C virus F protein in peripheral blood mononuclear cells from chronic hepatitis C patients.
    Yue M; Deng X; Zhai X; Xu K; Kong J; Zhang J; Zhou Z; Yu X; Xu X; Liu Y; Zhu D; Zhang Y
    Immunol Lett; 2013 May; 152(2):89-95. PubMed ID: 23680070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the inhibitory effect of antisense oligodeoxynucleotides on the growth of hepatitis C-associated hepatocellular carcinoma cells in vitro.
    Amin MA; Awadein MR; Gabr H
    Chin J Dig Dis; 2005; 6(3):142-8. PubMed ID: 16045605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection.
    Yang WT; Wu LW; Tseng TC; Chen CL; Yang HC; Su TH; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Liu CJ; Kao JH
    Medicine (Baltimore); 2016 Mar; 95(10):e2995. PubMed ID: 26962809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
    Sangro B; Gomez-Martin C; de la Mata M; Iñarrairaegui M; Garralda E; Barrera P; Riezu-Boj JI; Larrea E; Alfaro C; Sarobe P; Lasarte JJ; Pérez-Gracia JL; Melero I; Prieto J
    J Hepatol; 2013 Jul; 59(1):81-8. PubMed ID: 23466307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells.
    Yoon JC; Lim JB; Park JH; Lee JM
    J Virol; 2011 Dec; 85(23):12557-69. PubMed ID: 21937646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T and NK Cell-Based Immunotherapy in Chronic Viral Hepatitis and Hepatocellular Carcinoma.
    Fisicaro P; Boni C
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD81
    Ashraf Malik M; Ishtiyaq Ali Mirza J; Umar M; Manzoor S
    Viral Immunol; 2019 Dec; 32(10):453-462. PubMed ID: 31755827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers.
    Ishibashi M; Yamaguchi H; Hirotani Y; Sakurada A; Endo T; Sugitani M; Takayama T; Makishima M; Esumi M
    Arch Virol; 2018 Apr; 163(4):855-865. PubMed ID: 29248968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis?
    Hammad LN; Abdelraouf SM; Hassanein FS; Mohamed WA; Schaalan MF
    J Immunotoxicol; 2013; 10(4):380-6. PubMed ID: 23350952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.
    Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Fan ZP; Xu DP; Wang FS
    World J Gastroenterol; 2004 Apr; 10(8):1146-51. PubMed ID: 15069715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
    Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
    Samson A; Bentham MJ; Scott K; Nuovo G; Bloy A; Appleton E; Adair RA; Dave R; Peckham-Cooper A; Toogood G; Nagamori S; Coffey M; Vile R; Harrington K; Selby P; Errington-Mais F; Melcher A; Griffin S
    Gut; 2018 Mar; 67(3):562-573. PubMed ID: 27902444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.